Woman Gets First Dose of Breakthrough Cancer Treatment

Tracy Tomlinson just made medical history, and her courage could one day help millions of people fighting cancer.

The 58-year-old from Manchester became the first person in the world to receive ZI-MA4-1, a groundbreaking cancer therapy being tested at Christie NHS Foundation Trust. Tracy has been battling ovarian cancer since 2020, enduring multiple surgeries and rounds of chemotherapy as the disease kept returning.

When doctors told her about the clinical trial last year, she said yes almost immediately. "If it benefits me, absolutely fantastic," Tracy said. "But if it benefits other people in the future, that's important too."

The therapy works by combining two powerful cancer-fighting methods into one treatment. It uses natural killer cells from healthy donors, then engineers those cells to recognize and destroy tumors that produce a protein called Mage-A4. This protein appears in ovarian cancer, lung cancer, sarcomas, and head and neck cancers.

What makes this treatment special is that it's designed to work "off-the-shelf" rather than requiring custom engineering for each patient. A single manufacturing batch can produce hundreds of doses, which means faster access and lower costs for patients who need it most.

Dr. Jon Kim, Tracy's oncologist at the Christie, explained that she's "essentially getting somebody else's immune cells that have been engineered to 'see' her cancer." The trial will test the treatment on patients with several cancer types, many of whom have few other survival options.

The Ripple Effect

This moment represents more than one patient's hope. It signals a potential shift in how advanced cancer therapies reach people who need them most.

Currently, only about 15% of women with ovarian cancer survive five years or more after diagnosis. Personalized cell therapies have shown promise but remain expensive and time-consuming to produce. An off-the-shelf approach could open doors for thousands of patients who might otherwise never access cutting-edge treatments.

Professor Fiona Thistlethwaite, consultant medical oncologist at the Christie, called this an "exciting step forward" that could make advanced cell therapies available "to more patients more quickly and at a cheaper cost."

Tracy's optimism shines through her journey. "Every day that I wake up is a positive," she said. "You've got to have hope."

She refuses to accept limits on her future, asking herself why she can't still be here in 10 or 15 years. She has plans, goals, and things she wants to achieve.

Tracy's decision to be first wasn't easy—she admitted feeling "a little bit scary" about it. But her willingness to step into the unknown stems from wanting her struggle to mean something. "I don't want to have gone through everything I've gone through for nothing," she said. "I want to feel like I have made a difference."

Thanks to patients like Tracy, tomorrow's cancer treatments are being built today.